Kerri Fitzgerald

DocwireNews

The addition of tucatinib to trastuzumab and capecitabine better improved overall survival (OS) and progression-free survival (PFS; primary endpoint) compared with the addition of placebo in women with human epidermal growth factor receptor 2-positive metastatic <a href="https://www.docwirenews.com/abstracts/hem-onc-abstracts/body-composition-adherence-to-anthracycline-and-taxane-based-chemotherapy-and-survival-after-nonmetastatic-breast-cancer/">breast cancer</a>, according to a study published in The New England Journal of Medicine.Patients previously treated with trastuzumab, pertuzumab, and trastuzumab emtansine were randomized to receive tucatinib or placebo in combination with trastuzumab and capecitabine.<h2>Improved survival with the addition of tucatinib</h2>PFS at one year was 33.1% in the tucatinib, trastuzumab, and capecitabine group and 12.3% in the placebo group (hazard ratio [HR], 0.54; 95% CI, 0.42-0.71; P&lt;0.001). Median duration of PFS was 7.8 months and 5.6 months, respectively.Two-year OS was 44.9% in the trastuzumab, pertuzumab, and trastuzumab arm and 26.6% in the placebo cohort (HR, 0.66; 95% CI, 0.50-0.88; P=0.005), and median OS was 21.9 months and 17.4 months, respectively.<a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/tecentriq-cotellic-and-zelboraf-triple-threat-trumps-melanoma/">The triplet combination</a> also improved survival in a cohort of women with brain metastases: One-year PFS in this cohort was 24.9% with tucatinib, trastuzumab, and capecitabine versus 0% in the placebo group (HR, 0.48; 95% CI, 0.34-0.69; P&lt;0.001). Median PFS was 7.6 months and 5.4 months, respectively.Common adverse events associated with the tucatinib, trastuzumab, and capecitabine cohort included diarrhea, palmar-plantar erythrodysesthesia syndrome, nausea, fatigue, and vomiting. The researchers noted that the risks of diarrhea and elevated aminotransferase levels were particularly higher with the addition of tucatinib.

Roger Rodby, MD

Joel M. Topf, MD, FACP

Seldin Award Winner Advocates Online Education

NKF Spring Clinical Meetings 2025

Hatem Soliman, MD

The Future of Dendritic Cell Vaccines in HER2+ Breast Cancer: Toward De-Escalation of Chemotherapy

HER2 Breast Cancer

Jordana Jampel

Mechanism of Positive Association Between Parkinson’s Disease and Melanoma Revealed in New Research

Melanoma

Latest News

Study Identifies Triplet Combination for Heavily Pretreated HER2+ Breast Cancer

Breast Cancer News

The addition of tucatinib to trastuzumab and capecitabine better improved overall survival (OS) and progression-free survival (PFS; primary endpoint) compared with the ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe